207 related articles for article (PubMed ID: 30867264)
1. Clinical manifestations of homozygote allele carriers in Huntington disease.
Cubo E; Martinez-Horta SI; Santalo FS; Descalls AM; Calvo S; Gil-Polo C; Muñoz I; Llano K; Mariscal N; Diaz D; Gutierrez A; Aguado L; Ramos-Arroyo MA;
Neurology; 2019 Apr; 92(18):e2101-e2108. PubMed ID: 30867264
[TBL] [Abstract][Full Text] [Related]
2. Clinical manifestations of intermediate allele carriers in Huntington disease.
Cubo E; Ramos-Arroyo MA; Martinez-Horta S; Martínez-Descalls A; Calvo S; Gil-Polo C;
Neurology; 2016 Aug; 87(6):571-8. PubMed ID: 27402890
[TBL] [Abstract][Full Text] [Related]
3. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course.
Squitieri F; Gellera C; Cannella M; Mariotti C; Cislaghi G; Rubinsztein DC; Almqvist EW; Turner D; Bachoud-Lévi AC; Simpson SA; Delatycki M; Maglione V; Hayden MR; Donato SD
Brain; 2003 Apr; 126(Pt 4):946-55. PubMed ID: 12615650
[TBL] [Abstract][Full Text] [Related]
4. Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.
Moss DJH; Pardiñas AF; Langbehn D; Lo K; Leavitt BR; Roos R; Durr A; Mead S; ; ; Holmans P; Jones L; Tabrizi SJ
Lancet Neurol; 2017 Sep; 16(9):701-711. PubMed ID: 28642124
[TBL] [Abstract][Full Text] [Related]
5. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
; Biglan KM; Shoulson I; Kieburtz K; Oakes D; Kayson E; Shinaman MA; Zhao H; Romer M; Young A; Hersch S; Penney J; Marder K; Paulsen J; Quaid K; Siemers E; Tanner C; Mallonee W; Suter G; Dubinsky R; Gray C; Nance M; Bundlie S; Radtke D; Kostyk S; Baic C; Caress J; Walker F; Hunt V; O'Neill C; Chouinard S; Factor S; Greenamyre T; Wood-Siverio C; Corey-Bloom J; Song D; Peavy G; Moskowitz C; Wesson M; Samii A; Bird T; Lipe H; Blindauer K; Marshall F; Zimmerman C; Goldstein J; Rosas D; Novak P; Caviness J; Adler C; Duffy A; Wheelock V; Tempkin T; Richman D; Seeberger L; Albin R; Chou KL; Racette B; Perlmutter JS; Perlman S; Bordelon Y; Martin W; Wieler M; Leavitt B; Raymond L; Decolongon J; Clarke L; Jankovic J; Hunter C; Hauser RA; Sanchez-Ramos J; Furtado S; Suchowersky O; Klimek ML; Guttman M; Sethna R; Feigin A; Cox M; Shannon B; Percy A; Dure L; Harrison M; Johnson W; Higgins D; Molho E; Nickerson C; Evans S; Hobson D; Singer C; Galvez-Jimenez N; Shannon K; Comella C; Ross C; Saint-Hilaire MH; Testa C; Rosenblatt A; Hogarth P; Weiner W; Como P; Kumar R; Cotto C; Stout J; Brocht A; Watts A; Eberly S; Weaver C; Foroud T; Gusella J; MacDonald M; Myers R; Fahn S; Shults C
JAMA Neurol; 2016 Jan; 73(1):102-10. PubMed ID: 26569098
[TBL] [Abstract][Full Text] [Related]
6. Homozygotes and heterozygotes for ciliary neurotrophic factor null alleles do not show earlier onset of Huntington's disease.
Rubinsztein DC; Leggo J; Chiano M; Korn S; Dodge A; Norbury G; Rosser E; Craufurd D
Neurology; 1997 Sep; 49(3):890-2. PubMed ID: 9305364
[TBL] [Abstract][Full Text] [Related]
7. What is the impact of education on Huntington's disease?
López-Sendón JL; Royuela A; Trigo P; Orth M; Lange H; Reilmann R; Keylock J; Rickards H; Piacentini S; Squitieri F; Landwehrmeyer B; Witjes-Ane MN; Jurgens CK; Roos RA; Abraira V; de Yébenes JG;
Mov Disord; 2011 Jul; 26(8):1489-95. PubMed ID: 21432905
[TBL] [Abstract][Full Text] [Related]
8. Homozygote of spinocerebellar Ataxia type 3 correlating with severe phenotype based on analyses of clinical features.
Shang XJ; Xu HL; Yang JS; Chen PP; Lin MT; Qian MZ; Lin HX; Chen XP; Chen YC; Jiang B; Chen YJ; Chen WJ; Wang N; Zhou ZM; Gan SR
J Neurol Sci; 2018 Jul; 390():111-114. PubMed ID: 29801869
[TBL] [Abstract][Full Text] [Related]
9. Cognitive decline in Huntington's disease expansion gene carriers.
Baake V; Reijntjes RHAM; Dumas EM; Thompson JC; ; Roos RAC
Cortex; 2017 Oct; 95():51-62. PubMed ID: 28843844
[TBL] [Abstract][Full Text] [Related]
10. An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers.
Vaccarino AL; Anderson K; Borowsky B; Duff K; Giuliano J; Guttman M; Ho AK; Orth M; Paulsen JS; Sills T; van Kammen DP; Evans KR;
Mov Disord; 2011 Apr; 26(5):877-84. PubMed ID: 21370269
[TBL] [Abstract][Full Text] [Related]
11. Clinical phenotype in carriers of intermediate alleles in the huntingtin gene.
Savitt D; Jankovic J
J Neurol Sci; 2019 Jul; 402():57-61. PubMed ID: 31103960
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.
Killoran A; Biglan KM; Jankovic J; Eberly S; Kayson E; Oakes D; Young AB; Shoulson I
Neurology; 2013 May; 80(22):2022-7. PubMed ID: 23624566
[TBL] [Abstract][Full Text] [Related]
13. Biallelic mutations in huntington disease: A new case with just one affected parent, review of the literature and terminology.
Uhlmann WR; Peñaherrera MS; Robinson WP; Milunsky JM; Nicholson JM; Albin RL
Am J Med Genet A; 2015 May; 167A(5):1152-60. PubMed ID: 25736541
[TBL] [Abstract][Full Text] [Related]
14. The neurology and natural history of patients with indeterminate CAG repeat length mutations of the Huntington disease gene.
Panegyres PK; Goh JG
J Neurol Sci; 2011 Feb; 301(1-2):14-20. PubMed ID: 21147489
[TBL] [Abstract][Full Text] [Related]
15. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.
Lee JM; Ramos EM; Lee JH; Gillis T; Mysore JS; Hayden MR; Warby SC; Morrison P; Nance M; Ross CA; Margolis RL; Squitieri F; Orobello S; Di Donato S; Gomez-Tortosa E; Ayuso C; Suchowersky O; Trent RJ; McCusker E; Novelletto A; Frontali M; Jones R; Ashizawa T; Frank S; Saint-Hilaire MH; Hersch SM; Rosas HD; Lucente D; Harrison MB; Zanko A; Abramson RK; Marder K; Sequeiros J; Paulsen JS; ; Landwehrmeyer GB; ; Myers RH; ; MacDonald ME; Gusella JF;
Neurology; 2012 Mar; 78(10):690-5. PubMed ID: 22323755
[TBL] [Abstract][Full Text] [Related]
16. Missing the pathological expansion in Huntington disease: de novo c.51C>G variant on the expanded allele causing intrafamilial allele dropout.
Magri S; Nanetti L; Mongelli A; Rizzo E; Taroni F; Mariotti C; Gellera C
Am J Med Genet A; 2021 Feb; 185(2):397-400. PubMed ID: 33247537
[TBL] [Abstract][Full Text] [Related]
17. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea].
Vojvodić N; Culjković B; Romac S; Stojković O; Sternić N; Sokić D; Kostić VS
Srp Arh Celok Lek; 1998; 126(3-4):77-82. PubMed ID: 9863360
[TBL] [Abstract][Full Text] [Related]
18. Clinical and genetic characteristics in patients with Huntington's disease from China.
Yang J; Chen K; Wei Q; Chen Y; Cao B; Burgunder JM; Shang HF
Neurol Res; 2016 Oct; 38(10):916-20. PubMed ID: 27483361
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat.
Ruocco HH; Bonilha L; Li LM; Lopes-Cendes I; Cendes F
J Neurol Neurosurg Psychiatry; 2008 Feb; 79(2):130-5. PubMed ID: 17615168
[TBL] [Abstract][Full Text] [Related]
20. The relationship between CAG repeat length and clinical progression in Huntington's disease.
Ravina B; Romer M; Constantinescu R; Biglan K; Brocht A; Kieburtz K; Shoulson I; McDermott MP
Mov Disord; 2008 Jul; 23(9):1223-7. PubMed ID: 18512767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
